Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 10, 2005, Pages 2081-2087

  Wang, Grace J ^a   Sui, Xin Xin ^a   Simosa, Hector F ^a   Jain, Mukesh K ^a   Altieri, Dario C ^b   Conte, Michael S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Apoptosis; Intimal hyperplasia; Proliferation; Survivin

Indexed keywords

ADENOVIRUS VECTOR; INHIBITOR OF APOPTOSIS PROTEIN; PLATELET DERIVED GROWTH FACTOR; POLOXAMER; SURVIVIN;

ADVENTITIA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; VEIN GRAFT; VEIN WALL;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CELL DIVISION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENETIC VECTORS; GRAFT SURVIVAL; HUMANS; HYPERPLASIA; JUGULAR VEINS; MICROTUBULE-ASSOCIATED PROTEINS; MUSCLE, SMOOTH, VASCULAR; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RABBITS; SAPHENOUS VEIN; SIGNAL TRANSDUCTION;

EID: 26244460174     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000183885.66153.8a     Document Type: Article

References (32)

1. Belkin M, Whittemore AD. Infrainguinal Bypass. In: Rutherford RB, ed. Vascular Surgery, 5th ed. Philadelphia: WB Saunders Company; 2000.
2. Zhang L, Freedman NJ, Brian L, Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler Thromb Vasc Biol. 2004;24:470-476.
3. Shi Y, O'Brien JE Jr, Mannion JD, Morrison RC, Chung W, Fard A, Zalewski A. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation. 1997;95:2684-2693.
4. Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in apoE-deficient mice. Circ Res. 2003;93:76e-86.
5. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
6. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, Altieri DC. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med. 2002;8:987-994.
7. Simosa HF, Wang G, Sui X, Peterson T, Narra V, Altieri DC, Conte MS. Survivin expression is up-regulated in vascular injury and identifies a distinct cellular phenotype. J Vasc Surg. 2005;41:682-690.
8. Miyata T, Conte MS, Trudell LA, Mason D, Whittemore AD, Birinyi LK. Delayed exposure to pulsatile shear stress improves retention of human saphenous vein endothelial cells on seeded ePTFE grafts. J Surg Res. 1991;50:485-493.
9. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. [see comment]. J Clin Invest. 2001;108:981-990.
10. Caplice M, FRACP, Noel M, Aroney M., FRACP, Constantine N., Bett F, Nicholas JH, Cameron F, James. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture. J Am Coll Cardiol. 1997;29:1536-1541.
11. Gashler A, Bonthron D, Madden S, Rauscher FJI, Collins T, Sukhatme V. Human platelet-derived growth factor a chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci U S A. 1992;89:10984-10988.
12. Institute of Laboratory Animal Resources, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
13. Jiang Z, Wu L, Miller BL, Goldman DR, Fernandez CM, Abouhamze ZS, Ozaki CK, Berceli SA. A novel vein graft model: adaptation to differential flow environments. Am J Physiol Heart Circ Physiol. 2004;286:H240-H245.
14. Geng Y-J, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β. Arterioscler Thromb Vasc Biol. 1996;16:19-27.
15. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, Altieri DC. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol. 2001;158:1757-1765.
16. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10:1319-1328.
17. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247-3257.
18. Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem. 2004;279:2077-2084.
19. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613-2622.
20. Faries PL MM, Veith FJ, Ramirez JA, Suggs WD, Parsons RE, Sanchez LA, Lyon RT. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. J Vasc Surg. 1996;24:463-471.
21. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 2001;276:3238-3246.
22. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215-2223.
23. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114:1117-1127.
24. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. PNAS. 2004;101:15100-15105.
25. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996;94:1655-1664.
26. Li G, Chen S-J, Oparil S, Chen Y-F, Thompson JA. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 2000;101:1362-1365.
27. Fukuda S, Pelus LM. Activated H-Ras regulates hematopoietic cell survival by modulating Survivin. Biochem Biophys Res Commun. 2004;323:636-644.
28. Fukuda S, Mantel CR, Pelus LM. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood. 2004;103:120-127.
29. Ehsan A, Mann MJ. Antisense and gene therapy to prevent restenosis. Vasc Med. 2000;5:103-114.
30. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, Ferrara N, Martin JF, Zachary I, Simons M. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation. 2004;110:2436-2443.
31. Westerband A, Gentile AT, Hunter GC, Gooden MA, Aguirre ML, Berman SS, Mills JL. Intimal growth and neovascularization in human stenotic vein grafts. J Am Coll Surg. 2000;191:264-271.
32. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-8589.